Who Owns the Molecule?

✦The paradox: you cannot patent DMT, so they patent everything around it

N,N-DMT is old, natural, and exhaustively documented — it cannot be owned. What can be owned is the periphery: a particular formulation, a salt or crystal form, a deuterated analog, a dosing regimen, a delivery device, or a claim to use the molecule to treat a specific condition. This is the single most misunderstood point in the whole debate. When you read that a company has 'patented DMT,' it has almost always patented one of these peripheral things — not the molecule, which stays in the public domain.

✦Who holds what

The table below is a high-level map — assignee, patent or application number, the type of claim, the indication, and status. It records who is trying to own a slice, and how those attempts are faring. It is deliberately claim-type only: no chemistry, no methods. Numbers link to the public patent record so you can verify rather than trust. This landscape changes monthly; the date below is when it was last checked.

Landscape last checked 2026-07-21. Sources: Psychedelic Alpha — DMT Patent Tracker, Porta Sophia, and the public patent record (Google Patents / Espacenet). Status changes often — verify against the linked records.

✦The prior-art war

Because the molecule is ancient, many early filings were broad — claiming, in effect, obvious or already-known practice. Two watchdogs push back. Porta Sophia, a psychedelic prior-art library, files third-party submissions so examiners see the public record before granting; its work helped get all pending US claims rejected on GH Research's 5-MeO-DMT-for-depression application, and challenged 21 of 22 claims on a DMT-vape device. Freedom to Operate mounts formal post-grant challenges. And Usona Institute takes the opposite tack entirely — it refuses to patent and publishes openly, deliberately seeding prior art to keep the field open. A telling detail: GH Research's US claims were rejected while its European counterpart granted broadly — the same idea, opposite outcomes, one border apart.

✦Who can own a sacred plant?

The moral anchor of the whole debate predates the biotech rush. In 1986 an American, Loren Miller, was granted a US plant patent (PP5,751) on an ayahuasca vine cultivar he called 'Da Vine.' In 1999 a coalition of Amazonian Indigenous peoples (COICA) and the Center for International Environmental Law challenged it as biopiracy — the appropriation of a plant sacred to hundreds of communities. The patent office first rejected it, then reinstated it on technical grounds; it stood until it expired in 2003. The case remains the reference point for every question the current DMT rush raises about traditional knowledge, consent, and benefit-sharing.

✦Not everyone is enclosing

Three correctives worth holding. Compass Pathways, the name most associated with 'psychedelic patents,' has no DMT program — its patents are synthetic psilocybin. Philip Morris is, by some counts, the single largest holder of patents that merely mention DMT — a tobacco-chemistry artifact, not a medicine play; 'discloses DMT' is not 'owns DMT medicine.' And patents are not purely villainous: they are also how the very expensive clinical trials that could bring these into supervised care get funded. The honest frame is a contested territory, not a heist.

✦What the sources say

Running tracker of DMT/5-MeO-DMT patent filings, grants, and status changes.

Prior-art submissions that got GH Research's US 5-MeO-DMT claims rejected and challenged a DMT-vape patent.

Formal post-grant challenges to psychedelic patents.

The open-science counter-model: publish, do not patent.

The 'Da Vine' ayahuasca plant-patent challenge — the sacred-plant-ownership precedent.